Switch theme
Sign up to access all valuation multiples
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
2011
528
LTM Revenue $450M
LTM EBITDA -$435M
$6.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Madrigal Pharmaceuticals has a last 12-month revenue (LTM) of $450M and a last 12-month EBITDA of -$435M.
In the most recent fiscal year, Madrigal Pharmaceuticals achieved revenue of $180M and an EBITDA of -$450M.
Madrigal Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Madrigal Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $450M | XXX | $180M | XXX | XXX | XXX |
| Gross Profit | $429M | XXX | $174M | XXX | XXX | XXX |
| Gross Margin | 95% | XXX | 97% | XXX | XXX | XXX |
| EBITDA | -$435M | XXX | -$450M | XXX | XXX | XXX |
| EBITDA Margin | -97% | XXX | -250% | XXX | XXX | XXX |
| EBIT | -$408M | XXX | -$498M | XXX | XXX | XXX |
| EBIT Margin | -91% | XXX | -276% | XXX | XXX | XXX |
| Net Profit | -$372M | XXX | -$466M | XXX | XXX | XXX |
| Net Margin | -83% | XXX | -259% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $17.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Madrigal Pharmaceuticals's stock price is $311.
Madrigal Pharmaceuticals has current market cap of $6.9B, and EV of $6.2B.
See Madrigal Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.2B | $6.9B | XXX | XXX | XXX | XXX | $-17.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Madrigal Pharmaceuticals has market cap of $6.9B and EV of $6.2B.
Madrigal Pharmaceuticals's trades at 34.3x EV/Revenue multiple, and -13.7x EV/EBITDA.
Equity research analysts estimate Madrigal Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Madrigal Pharmaceuticals has a P/E ratio of -18.6x.
See valuation multiples for Madrigal Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.9B | XXX | $6.9B | XXX | XXX | XXX |
| EV (current) | $6.2B | XXX | $6.2B | XXX | XXX | XXX |
| EV/Revenue | 13.7x | XXX | 34.3x | XXX | XXX | XXX |
| EV/EBITDA | -14.2x | XXX | -13.7x | XXX | XXX | XXX |
| EV/EBIT | -15.2x | XXX | -12.4x | XXX | XXX | XXX |
| EV/Gross Profit | 14.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -18.6x | XXX | -14.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -13.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMadrigal Pharmaceuticals's last 12 month revenue growth is 103%
Madrigal Pharmaceuticals's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.3M for the same period.
Madrigal Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Madrigal Pharmaceuticals's rule of X is 162% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Madrigal Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 103% | XXX | 149% | XXX | XXX | XXX |
| EBITDA Margin | -97% | XXX | -250% | XXX | XXX | XXX |
| EBITDA Growth | -47% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -147% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 162% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 131% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 373% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Madrigal Pharmaceuticals acquired XXX companies to date.
Last acquisition by Madrigal Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Madrigal Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Madrigal Pharmaceuticals founded? | Madrigal Pharmaceuticals was founded in 2011. |
| Where is Madrigal Pharmaceuticals headquartered? | Madrigal Pharmaceuticals is headquartered in United States of America. |
| How many employees does Madrigal Pharmaceuticals have? | As of today, Madrigal Pharmaceuticals has 528 employees. |
| Who is the CEO of Madrigal Pharmaceuticals? | Madrigal Pharmaceuticals's CEO is Mr. William John Sibold. |
| Is Madrigal Pharmaceuticals publicy listed? | Yes, Madrigal Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Madrigal Pharmaceuticals? | Madrigal Pharmaceuticals trades under MDGL ticker. |
| When did Madrigal Pharmaceuticals go public? | Madrigal Pharmaceuticals went public in 2007. |
| Who are competitors of Madrigal Pharmaceuticals? | Similar companies to Madrigal Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Madrigal Pharmaceuticals? | Madrigal Pharmaceuticals's current market cap is $6.9B |
| What is the current revenue of Madrigal Pharmaceuticals? | Madrigal Pharmaceuticals's last 12 months revenue is $450M. |
| What is the current revenue growth of Madrigal Pharmaceuticals? | Madrigal Pharmaceuticals revenue growth (NTM/LTM) is 103%. |
| What is the current EV/Revenue multiple of Madrigal Pharmaceuticals? | Current revenue multiple of Madrigal Pharmaceuticals is 13.7x. |
| Is Madrigal Pharmaceuticals profitable? | Yes, Madrigal Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Madrigal Pharmaceuticals? | Madrigal Pharmaceuticals's last 12 months EBITDA is -$435M. |
| What is Madrigal Pharmaceuticals's EBITDA margin? | Madrigal Pharmaceuticals's last 12 months EBITDA margin is -97%. |
| What is the current EV/EBITDA multiple of Madrigal Pharmaceuticals? | Current EBITDA multiple of Madrigal Pharmaceuticals is -14.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
